<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808949</url>
  </required_header>
  <id_info>
    <org_study_id>MTN-029/IPM 039</org_study_id>
    <nct_id>NCT02808949</nct_id>
    <nct_alias>NCT02658227</nct_alias>
  </id_info>
  <brief_title>Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women</brief_title>
  <official_title>Phase 1 Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 PK Study of the Dapivirine Vaginal Ring in Lactating Women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PK Study of the Dapivirine Vaginal Ring in Lactating Women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">March 3, 2018</completion_date>
  <primary_completion_date type="Actual">March 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>14 Days</time_frame>
    <description>To assess the pharmacokinetics of dapivirine vaginal ring used for 14 consecutive days in lactating women</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of dapivirine ring in lactating women</measure>
    <time_frame>14 days</time_frame>
    <description>To assess safety and tolerability of dapivirine vaginal ring used for 14 consecutive days in lactating women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to dapivirine vaginal ring use in lactating women</measure>
    <time_frame>14 days</time_frame>
    <description>To assess adherence to dapivirine vaginal ring use in lactating women</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Age Groups</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapivirine levels in breast milk will be measured in 16 participants. All participants will wear the Dapivirine Vaginal Ring for 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine</intervention_name>
    <description>Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.</description>
    <arm_group_label>Age Groups</arm_group_label>
    <other_name>Dapivirine vaginal ring</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Women must meet all of the following criteria (by self-report, unless otherwise indicated)&#xD;
        to be eligible for inclusion in the study:&#xD;
&#xD;
          1. Age 18 or older at screening as verified per site SOP&#xD;
&#xD;
          2. Per participant report, at least 6 weeks postpartum at Enrollment&#xD;
&#xD;
          3. Willing and able to provide written informed consent to be screened for and take part&#xD;
             in the study&#xD;
&#xD;
          4. Willing and able to provide adequate locator information, as defined in site SOP&#xD;
&#xD;
          5. Willing and able to communicate in spoken and written English&#xD;
&#xD;
          6. HIV-1/2 uninfected at Screening and Enrollment, per applicable algorithm in Appendix&#xD;
             II and willing to receive HIV test results Note: HIV-1/2 screening may be omitted at&#xD;
             Enrollment if the time between Screening and Enrollment is &lt; 30 days&#xD;
&#xD;
          7. Prior to Enrollment, breastfeeding of child has stopped&#xD;
&#xD;
          8. Participant has no intention of providing expressed breast milk to her child(ren) or&#xD;
             to others for consumption after initiation of study product Note: Providing stored&#xD;
             breast milk to child(ren) that has been expressed prior to study product exposure is&#xD;
             not exclusionary&#xD;
&#xD;
          9. Willing and able to express breast milk at least twice daily for the duration of study&#xD;
             drug exposure&#xD;
&#xD;
         10. Per participant report, using an effective method of contraception at Enrollment, and&#xD;
             intending to continue the use of an effective method for the duration of study&#xD;
             participation. Effective methods for MTN-029/IPM 039 include: hormonal methods (except&#xD;
             contraceptive VRs), intrauterine device (IUD) inserted at least 28 days prior to&#xD;
             enrollment, engages in sex exclusively with women, sterilized (self or partner), or&#xD;
             sexually abstinent for the past 90 days&#xD;
&#xD;
         11. Women over the age of 21 (inclusive) must have documentation of a satisfactory Pap&#xD;
             within the past 3 years prior to Enrollment consistent with Grade 0 according to the&#xD;
             Female Genital Grading Table for Use in Microbicide Studies (Addendum 1 to the DAIDS&#xD;
             Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0,&#xD;
             November 2007), or satisfactory evaluation with no treatment required of Grade 1 or&#xD;
             higher Pap result&#xD;
&#xD;
         12. At Screening, participant states a willingness to refrain from receptive sexual&#xD;
             activity (including penile-vaginal intercourse, anal intercourse, receptive oral&#xD;
             intercourse, finger stimulation) and from inserting any non-study objects into the&#xD;
             vagina (including tampons, sex toys, female condoms, diaphragms, menstrual cups,&#xD;
             cervical caps or any other vaginal barrier method, etc.), for 24 hours prior to each&#xD;
             clinic visit.&#xD;
&#xD;
         13. At Screening, participant states a willingness to refrain from the use of vaginal&#xD;
             products, including, spermicides, lubricants, contraceptive VRs, douches, vaginal&#xD;
             medications, etc., for the duration of study participation&#xD;
&#xD;
         14. Per participant report at Screening and Enrollment, agrees not to participate in other&#xD;
             research studies involving drugs, medical devices, vaginal products, vaccines or&#xD;
             breast milk sampling for the duration of study participation Note: Participation in&#xD;
             observational studies is not exclusionary&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Women who meet any of the following criteria (by self-report, unless otherwise indicated)&#xD;
        will be excluded from the study:&#xD;
&#xD;
          1. Participant report of any of the following:&#xD;
&#xD;
               -  History of adverse reaction to any component of dapivirine VR&#xD;
&#xD;
               -  Participation in investigational drug or device trial within 30 days prior to the&#xD;
                  Enrollment Visit (Day 0)&#xD;
&#xD;
               -  Use of vaginal medication(s) 5 days prior to Enrollment (Day 0)&#xD;
&#xD;
               -  Complication of lactation requiring treatment, e.g., mastitis&#xD;
&#xD;
          2. At the time of Screening and Enrollment, clinical evidence of milk supply less than 1&#xD;
             ounce per expression&#xD;
&#xD;
          3. As determined by the IoR/designee, any significant uncontrolled active or chronic&#xD;
             cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric,&#xD;
             endocrine, respiratory, immunologic disorder or infectious disease&#xD;
&#xD;
          4. Grade 2 or higher AST/ALT at Screening Visit:&#xD;
&#xD;
             Note: Otherwise eligible participants with an exclusionary AST/ALT may be retested&#xD;
             during the screening process.&#xD;
&#xD;
          5. Positive urine pregnancy test at screening or enrollment&#xD;
&#xD;
          6. Diagnosed with urinary tract infection (UTI) at Screening or Enrollment Note:&#xD;
             Otherwise eligible participants diagnosed with UTI during screening are offered&#xD;
             treatment and may be enrolled after completing treatment and all symptoms have&#xD;
             resolved.&#xD;
&#xD;
          7. Diagnosed with an STI or a reproductive tract infection (RTI) requiring treatment per&#xD;
             current Centers for Disease Control and Prevention (CDC) guidelines at Screening or&#xD;
             Enrollment&#xD;
&#xD;
          8. On pelvic exam, any of the following findings:&#xD;
&#xD;
               -  Incomplete postpartum involution of the uterus&#xD;
&#xD;
               -  Clinically apparent Grade 2 or higher pelvic exam finding (observed by study&#xD;
                  staff)&#xD;
&#xD;
          9. Use of oral and/or vaginal preparations of antibiotic or antifungal medications within&#xD;
             5 days of Enrollment&#xD;
&#xD;
         10. At Screening or Enrollment, any social or medical condition that, in the&#xD;
             investigator's opinion, would preclude informed consent, make study participation&#xD;
             unsafe, complicate interpretation of study outcome data, or otherwise interfere with&#xD;
             achieving the study objectives&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Hoesley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>December 18, 2015</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>Lactating Women</keyword>
  <keyword>Healthy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapivirine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

